Every afternoon, you can find two completely different worlds coexisting side by side on Instagram, sometimes colliding. Posts celebrating a range of body types, affirmations about body trust, and therapists reassuring people that hunger is not a bad thing can all be found in one corner. Advertisements for GLP-1 clinics that promise a new relationship with food through a weekly shot in the stomach, celebrity interviews about “managing appetite,” and before-and-after pictures captioned with injection schedules are examples of the other. Both communities are expanding. They’re both noisy. Between them lies a real cultural question that no one has yet satisfactorily addressed: can the body positivity movement maintain its footing in a world where pharmaceutical appetite suppression has become the norm after ten years of cautious, hard-won ground?
Clinical medicine finds it difficult to dispute the weight loss outcomes of Ozempic and its cousin Wegovy, both semaglutide and GLP-1 receptor agonists that were first created for type 2 diabetes. On average, users lose between 15 and 20 percent of their body weight. By slowing stomach emptying and changing the brain’s reward signals related to food, the drugs make eating seem less urgent, less enjoyable, and, for some, almost pointless.
| Category | Detail |
|---|---|
| Drug Names | Ozempic (semaglutide), Wegovy — GLP-1 receptor agonists |
| Originally Developed For | Type 2 diabetes management |
| Weight Loss Effect | Average 15–20% body weight reduction in clinical users |
| How It Works | Slows stomach emptying; alters brain reward signals around food; mimics GLP-1 gut hormone |
| Key Cultural Concern | Renewed reinforcement of thinness as the societal ideal |
| Intuitive Eating (IE) | A framework focused on rebuilding trust with hunger/fullness cues; rejecting diet culture |
| Health at Every Size (HAES) | A health philosophy emphasising well-being behaviours over weight-focused outcomes |
| Body Positivity Movement | Cultural movement advocating acceptance of all body sizes, challenging beauty and weight norms |
| Industry Response | WeightWatchers partnering with GLP-1 clinics; major weight-loss brands repositioning around medication |
| Eating Disorder Concern | No adequate research yet on GLP-1 use in people with existing eating disorders (per NEDA) |
| Reference | National Eating Disorders Association |
The cultural collision is fascinating because of that final aspect. Body positivity practitioners have spent years advocating intuitive eating, which is based on the exact opposite premise: that hunger signals are reliable, that the body knows what it needs, and that the way to a long-lasting, non-punishing relationship with food is to re-establish a connection with those cues. Ozempic does more than simply refute that notion. It overrides it by design.
It’s important to note that the movement’s discomfort with this is genuine and not wholly unjust. WeightWatchers, one of the most prominent representations of the diet culture’s control over women’s bodies for decades, announced collaborations with GLP-1 clinics, reframing the traditional promise of thinness in terms of medicine. Ozempic was portrayed on social media as a lifestyle option rather than a drug, a way to look a certain way instead of treating a particular illness. Influencers who had previously kept quiet about their bodies started sharing photos of their dramatic makeovers. In a lab coat, the thin ideal—which proponents of body positivity had spent years attempting to remove from its pivotal role in popular culture—returned with a bang.
As you watch this happen, you get the impression that the movement wasn’t totally ready for it. The foundation of body positivity’s arguments was the idea that diet culture was a choice, a set of beliefs and practices that people and organizations could be convinced to give up. It is more difficult to categorize a pharmaceutical product as harmful messaging when it results in real, medically proven weight loss at a physiological level. In 2023, The Atlantic posed the straightforward question: could Ozempic undermine the body positivity movement? It seemed a little provocative at the time. Now that the GLP-1 era is a few years older, it seems more like a genuine reckoning.
Intuitive eating practitioners and HAES-aligned clinicians have been navigating this cautiously, and not without some internal conflict. In general, the official stance is that the right to take medication is part of body autonomy; choosing Ozempic is not a betrayal of one’s values any more than taking blood pressure medication. The question, according to practitioners, is whether intuitive eating promotes behavioral and psychological changes that coexist with the drug rather than being replaced by it. And to be honest, that is the main issue.
The years of diet mentality, food guilt, and complex emotional relationships with eating that many users bring to the experience are not addressed by GLP-1 medications, although they do suppress appetite. The hunger is managed by the medication. Nothing else is automatically altered. When people stop taking it, they frequently experience rapid weight gain along with a panicked return to restrictive behaviors, which is precisely the cycle that intuitive eating was intended to break.
The National Eating Disorders Association has carefully noted that the effects of GLP-1 medications on individuals with pre-existing eating disorders have not yet been thoroughly studied. That gap is important. In some cases, a drug that essentially mutes hunger signals and lessens the enjoyment of eating may actually reinforce the very patterns that eating disorder treatment aims to break. This worry might be exaggerated. It’s also possible that it isn’t, and the data simply hasn’t caught up to a medication that, in a remarkably short period of time, went from being a specialized diabetes treatment to a cultural phenomenon.
Beneath the catchphrases and Instagram affirmations, body positivity has always argued that health cannot be reduced to a number on a scale and that pursuing well-being through external control, shame, and restriction causes more harm than good. The existence of semaglutide does not refute that argument. Whether Ozempic and intuitive eating can truly coexist in a single person’s life without one undermining the other is still up for debate.
The more difficult question, however, is what happens culturally when a drug makes significant weight loss possible in a way that diet culture never quite managed; does this normalize thinness as the default goal once more, albeit through a different mechanism? For ten years, the body positivity movement maintained that the objective was flawed. That argument has not been altered by Ozempic. It has simply made it much harder to hear.
